Factors Requiring Midazolam in Addition to Systemic Opioids to Control Dyspnea in Cancer Patients at the End of Life

Yuka OKUDA; Toshiyuki KURIYAMA; Yoshi TSUKIYAMA; Yoshinobu MATSUDA; Takashi YAMAGUCHI; Masanori MORI; Toshio SHIMOKAWA; Tomoyuki KAWAMATA

Return

Factors Requiring Midazolam in Addition to Systemic Opioids to Control Dyspnea in Cancer Patients at the End of Life

VernacularTitle:呼吸困難のコントロールがオピオイドのみでは難しくミダゾラムを併用した終末期がん患者の要因
Author: Yuka OKUDA ¹ ; Toshiyuki KURIYAMA ¹ ; Yoshi TSUKIYAMA ¹ ; Yoshinobu MATSUDA ² ; Takashi YAMAGUCHI ³ ; Masanori MORI ⁴ ; Toshio SHIMOKAWA ⁵ ; Tomoyuki KAWAMATA ¹
Author Information

1. Division of Palliative Care, Department of Anesthesiology, School of Medicine, Wakayama Medical University
2. Department of Psychosomatic Internal Medicine, Kinki-Chuo Chest Medical Center
3. Department of Palliative Medicine, Kobe University Graduate School of Medicine
4. Division of Palliative and Supportive Care, Seirei Mikatahara General Hospital
5. Clinical Study Support Center, Wakayama Medical University
Keywords: cancer patient; dyspnea; opioid; midazolam
From:Palliative Care Research 2023;18(4):247-252
CountryJapan
Language:Japanese
Abstract: Background: Factors requiring midazolam in addition to systemic opioids to control dyspnea in cancer patients have yet to be evaluated. Methods: We retrospectively analyzed data for cancer patients who received systemic opioids to relieve dyspnea from April 2019 to July 2021 in Wakayama Medical University Hospital, Japan. Patients were divided into an opioid-alone group and an opioid plus midazolam group, according to the treatment of dyspnea. Results: The total of 107 patients included 85 patients (79.4%) in the opioid alone group and 22 patients (20.6%) in the opioid plus midazolam group. Age<60 years (p=0.004) and male sex (p=0.034) was significantly associated with the addition of midazolam. Multivariate analysis found age <60 years (OR=5.34, 95%CI: 1.66–17.21; p=0.005) was associated with the addition of midazolam. Conclusion: Age <60 years is factor requiring midazolam in addition to systemic opioids to control dyspnea in cancer patients.